Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 29

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 29
---
 of the holder upon surrender of the warrant to us together with the appropriate instruments of transfer and payment of funds sufficient to pay any transfer taxes (if applicable). Fractional Shares No fractional ADSs or ordinary shares will be issued upon the exercise of the warrants. Rather, the number of ADSs to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price. Exchange Listing There is no established trading market for the warrants, and we do not expect a market to develop. We do not intend to apply for a listing for the warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the warrants will be limited. S - 15 No Rights as an ADS Holder Except as otherwise provided in the warrants or by virtue of the holders’ ownership of ADS or ordinary shares, the holders of warrants do not have the rights or privileges of holders of ADS or our ordinary shares, including any voting rights, until such warrant holders exercise their warrants. The holders of warrants do not have any rights of holders of ADSs until such time as ADSs are acquired, following exercise of warrants for ordinary shares and subsequent deposit thereof with the depositary and delivery of ADSs. Governing Law The warrants are governed by New York law. Pre-Funded Warrants The following is a summary of the material terms and provisions of the pre-funded warrants that are being offered hereby. This summary is subject to and qualified in its entirety by the form of pre-funded warrants, which has been provided to the investor in this offering and which will be filed with the SEC as an exhibit to our Report of Foreign Private Issuer on Form 6-K in connection with this offering and incorporated by reference into the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of warrant for a complete description of the terms and conditions of the pre-funded warrants. The term “pre-funded” refers to the fact that the purchase price of our ADSs in this offering includes almost the entire exercise price that will be paid under the pre-funded warrants, except for a nominal remaining exercise price of $0.0001. The purpose of the pre-funded warrants is to limit the beneficial ownership of the investors to 4.99% (or, at the election of the holder, 9.99%) of our ordinary shares (including ordinary shares represented by ADS